> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Panel Rejects Astrazeneca’s Camizestrant In Closely Watched Vote
- URL: https://www.fdaweb.com/fda-panel-rejects-astrazenecas-camizestrant-in-closely-watched-vote/
- Published: 2026-04-30T12:00:00.000Z
- Updated: 2026-09-14T13:38:21.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161075

FDA’s Oncologic Drugs Advisory Committee has voted 6 to 3 against supporting AstraZeneca’s investigational breast cancer therapy camizestrant, dealing a setback to the company’s efforts to bring the oral SERD to market. Camizestrant is being developed for patients with hormone receptor–positive, HER2-negative breast cancer harboring ESR1 mutations, with AstraZeneca positioning the therapy as an earlier-line option guided by circulating tumor DNA (ctDNA) testing. Panel members raised concerns similar to those outlined by FDA reviewers in a briefing document released in advance of the panel meeting ([see earlier story](https://www.fdaweb.com/reviewers-brief-odac-on-camizestrant-concerns/)).

The negative vote followed extensive debate over whether the drug’s clinical benefit — primarily based on progression-free survival in the SERENA-6 trial — translates into meaningful outcomes for patients. Panelists raised concerns about the trial’s design, which measured disease progression from a molecular signal rather than traditional imaging-based progression, as well as the lack of mature overall survival data.

Safety considerations, including cardiac effects such as bradycardia, were also discussed, though the central issue remained uncertainty over clinical relevance and treatment timing.

The decision marks a high-profile test of ctDNA-guided treatment strategies, an emerging approach that seeks to intervene earlier in cancer progression based on molecular changes rather than radiographic evidence.

While advisory committee recommendations are not binding, the FDA typically follows panel guidance. The agency is expected to make a final regulatory decision on camizestrant in the coming months.